Dapagliflozin Patent Expiration

Dapagliflozin is used for treating heart failure and type 2 diabetes. It was first introduced by Astrazeneca Ab in its drug Farxiga on Jan 8, 2014. 2 different companies have introduced drugs containing Dapagliflozin.


Dapagliflozin Patents

Given below is the list of patents protecting Dapagliflozin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Farxiga US10973836 Methods of treating heart failure with reduced ejection fraction Mar 09, 2040 Astrazeneca Ab
Farxiga US11826376 Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same Jul 18, 2039 Astrazeneca Ab
Farxiga US11903955 Methods of treating heart failure with reduced ejection fraction Mar 09, 2040 Astrazeneca Ab
Farxiga US6414126 C-aryl glucoside SGLT2 inhibitors and method Oct 04, 2020

(Expired)

Astrazeneca Ab
Farxiga US6515117 C-aryl glucoside SGLT2 inhibitors and method Oct 04, 2025 Astrazeneca Ab
Farxiga US6936590 C-aryl glucoside SGLT2 inhibitors and method Oct 04, 2020

(Expired)

Astrazeneca Ab
Farxiga US7456254 Polymer-based sustained release device Jun 30, 2025 Astrazeneca Ab
Farxiga US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor Aug 19, 2028 Astrazeneca Ab
Farxiga US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same Dec 16, 2029 Astrazeneca Ab
Farxiga US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor Mar 21, 2028 Astrazeneca Ab
Farxiga US8329648 Methods for treating diabetes and reducing body weight Aug 18, 2026 Astrazeneca Ab
Farxiga US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor Mar 21, 2028 Astrazeneca Ab
Farxiga US8431685 Polymer-based sustained release device Apr 13, 2025 Astrazeneca Ab
Farxiga US8461105 Polymer-based sustained release device Apr 13, 2025 Astrazeneca Ab
Farxiga US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same Jun 20, 2027 Astrazeneca Ab
Farxiga US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May 26, 2030 Astrazeneca Ab
Farxiga US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor Mar 21, 2028 Astrazeneca Ab
Farxiga US8721615 Ampoule comprising an ampoule holder Jan 18, 2030 Astrazeneca Ab
Farxiga US8906851 Method for treating diabetes Aug 18, 2026 Astrazeneca Ab
Farxiga US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor Oct 04, 2020

(Expired)

Astrazeneca Ab
Farxiga US9238076 Polymer-based sustained release device Apr 15, 2024

(Expired)

Astrazeneca Ab


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳

Dapagliflozin Generics

Several generic applications have been filed for Dapagliflozin.

Given below is the list of companies who have filed for Dapagliflozin generic.


1. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dapagliflozin. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
5MG tablet Discontinued ORAL N/A Feb 22, 2022
10MG tablet Discontinued ORAL N/A Feb 22, 2022